Search results for " Europe" in Articles / App Notes
Article
Modern Manufacturing Key to More Effective Vaccines
Modern Manufacturing Key to More Effective Vaccines
Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.
By Jill Wechsler
…
Article
Biopharmaceutical Market in Asia: Q&A with Günter Jagschies, Strategic Customer Relations Leader, Cytiva
Korea, Japan, and Singapore, in particular, have a well-established biopharma industry with development and manufacturing capabilities that compete with businesses in North America or Europe at eye le…
Article
Process Development: What May Lie Ahead in 2018?
In Europe, the United Kingdom’s pending departure from the European Union left many unanswered questions about drug approvals and inspections.
Top Articles of 2017
Here is a rundown of som…
Article
Reducing Cross-Contamination Risks in Process Chromatography
In October 2017, Cytiva opened its first 3-D printing lab (the Innovative Design and Advanced Manufacturing Technology Center for Europe) in Uppsala, Sweden. The center combines advanced manufacturing…
Article
Unifying Continuous Biomanufacturing Operations
Prior to the Tiainen/Novo Nordisk patent, Bayer HealthCare was granted a patent in Europe in 2016 for the integrated continuous manufacture of biologics. The two proposed platforms in that patent, how…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
In contrast, Zarxio has been available in Europe since 2006. There are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 bil…
Article
Managing Risk in Raw Material Sourcing
The company has established sites in the United States, Europe, and India, based on customer demand for local materials. For Avantor’s offshore suppliers, he adds, the use of (local) advisors helps en…
Article
Biosimilars to Drive Modern Manufacturing Approaches
Concerns about adverse events have diminished as biosimilar use has expanded in Europe. As more competitors enter biosimilar markets, Gal expects discounts will rise from the 30% range to more than 75…
Article
A Q&A with Eric Langer: CMOs Embrace New Technology
The trends in the US appear to be slightly more aggressive than in Europe.
What was the most surprising trend revealed in the 13th Annual Report and Survey of BioManufacturing? Why?
The biop…
Article
Managing Biomanufacturing Capacity Expectations
In Europe, because physicians seem to be more accepting of biosimilars, market penetration forecasts may be a bit more clear—but in the United States, physician acceptance and prescribing practices (a…